Seeman P.: Dopamine receptors and psychosisSci Med2:28-37, 1995
2.
Seeman P., Chau-Wong M., Tedesco J., et al: Brain receptors for antipsychotic drugs and dopamine: direct binding assaysProc Natl Acad Sci USA72:4376-4380, 1975
3.
Spano PF, Govoni S., Trebucchi M.: Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous systemAdv Biochem Psychopharmacol19:155-165, 1978
4.
Roth BL, Meltzer HY: The role of serotonin in schizophrenia in Bloom FE, Kupfer DJ (eds): Psychopharmacology : The Fourth Generation of Progress.New York, NY,Raven Press,1995 , pp 1215-1228
5.
Carpenter WT , Conley RR, Buchanan RW, et al: Patient response and resource management: Another view of clozapine treatment of schizophreniaAm J Psychiatry1252:827-832, 1995
6.
Meltzer HY: Atypical antipsychotic drugs in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress.New York, NY, Raven Press, 1995, pp 1277-1286
7.
Chouinard G. , Jones BJ, Remington G., et al : A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patientsJ Clin Psychopharmacol13:25-40, 1993
8.
Pies R.: Risperidone: An atypical first-line antipsychoticPharmacy Therap Oct1995, pp 623-635
9.
Musser WS, Kirisci L.: Critique of the Canadian multicenter placebo-controlled study of risperidone and haloperidolJ Clin Psychopharmacol15:226-228, 1995
Seeman P., Hong-Chang G., Van Tol H.H.M.: Dopamine D4 receptors elevated in schizophreniaNature365: 441-445,1993
12.
Physician's Desk Reference [Sandoz labeling instructions for Clozaril], Medical Economics Data Production Co, Montvale, NJ, 1995, p 2150
13.
Suppes T., McElroy SL, Gilbert J., et al: Clozapine in the treatment of dysphoric maniaBiol Psychiatry32:270-280, 1992
14.
Friedman JH , Lannon MC: Clozapine in the treatment of psychosis in Parkinson's diseaseNeurology39:1219-1221, 1989
15.
Michaels ML , Crimson ML, Robert S., et al: Clozapine response and adverse effects in nine brain-injured patientsJ Clin Psychopharmacol13:192-203, 1993
16.
Frankenburg FR, Zanarini MC: Clozapine treatment of borderline patients: A preliminary studyCompr Psychiatry34:402-405, 1993
17.
Buckley PF, Meltzer HY: Treatment of schizophrenia in Schatzberg AF, Nemeroff CB (eds): The American Psychiatric Press Textbook of Psychopharmacology.Washington DC, American Psychiatric Press,1995, pp 615-640
18.
Pfister GM, Hanson DR, Roerig JL, et al: Clozapine-induced agranulocytosis in a Native American: HLA typing and further support for an immune-mediated mechanismJ Clin Psychiatry53:242-244, 1992
19.
Koller WC, Megaffin BB: Parkinson's disease and Parkinsonism in Coffey CE, Cummings JL (eds): American Psychiatric Press Textbook of Geriatric Neuropsychiatry.Washington DC, American Psychiatric Press, Inc., 1994, pp 434-456
20.
Baldessarini RJ: Use of risperidone update, McLean Hospital, Belmont, MA memorandum, March 24,1995
21.
Borison RL, Diamond BI, Pathiragja A., et al : Clinical overview of risperidone in Meltzer HY (ed): Novel Atypical Antipsychotic Drugs.New York, NY, Raven Press, 1992, pp 223-239
22.
Jeanblanc W. , Davis YB: Risperidone for treating dementia-associated aggressionAm J Psychiatry152:1239, 1995 (letter)
23.
Dwight MM, Keck PE, Stanton SP, et al: Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorderLancet344:554-555, 1994
24.
Ciraulo DA, Shader RI, Greenblatt DJ: Drug interactions in psychopharmacology, in Shader RI (ed): Manual of Psychiatric Therapeutics, 2nd ed. Boston, MA, Little, Brown & Co , 1994, pp 143-156
25.
Honer WG, MacEwan GW, Kopala L., et al: A clinical study of clozapine treatment and predictors of response in a Canadian sampleCan J Psychiatry40:208-211, 1995
